Medical Centre Hungarian Defence Forces
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At the Medical Centre Hungarian Defence Forces, researchers are exploring innovative approaches to prevent and treat atherosclerotic cardiovascular disease, atrial fibrillation, myocardial infarction, and stroke. The studies focus on new oral anticoagulants, lipid‑targeting therapies, and agents that aim to lower the incidence of major adverse cardiovascular events.
- Evaluation of novel oral anticoagulants for stroke prevention
- Investigation of RNA‑based therapies to reduce lipoprotein(a) levels
- Assessment of anti‑platelet strategies after acute ischemic stroke
- Study of treatments to prevent recurrent myocardial infarction
- Exploration of therapeutic options for atrial fibrillation patients unsuitable for standard anticoagulation
These trials aim to improve cardiovascular risk management and enhance long‑term outcomes for patients with high‑risk heart and vessel conditions.
Digestive System Diseases
The gastroenterology department at the centre conducts research on inflammatory bowel conditions, notably ulcerative colitis. Clinical work evaluates emerging biologics and small molecules designed to achieve deeper remission and better quality of life for affected individuals.
- Testing of new anti‑inflammatory agents for ulcerative colitis
- Evaluation of targeted biologic therapies on disease activity
- Improvement of non‑invasive monitoring techniques
- Long‑term safety assessment of novel treatment regimens
- Analysis of patient‑reported outcomes and quality‑of‑life measures
The goal is to expand therapeutic options and provide more durable disease control for patients with chronic digestive disorders.
Hemic and Lymphatic Diseases
Studies at the centre address bleeding disorders such as hemophilia A and B, focusing on prophylactic factor replacement strategies. Research includes advanced imaging to track joint health and comparisons of extended‑half‑life products to optimize patient care.
- Assessment of prophylactic factor concentrates for bleed prevention
- Monitoring joint status using ultrasound imaging
- Comparison of extended‑half‑life clotting factor products
- Evaluation of major bleeding incidence across treatment arms
- Strategies to improve adherence to long‑term prophylaxis
These investigations strive to reduce bleeding episodes, preserve joint function, and enhance overall quality of life for individuals with hemophilia.
Nutritional and Metabolic Diseases
The centre’s metabolic research targets conditions like obesity, type 2 diabetes, and related metabolic disturbances. Trials assess novel agents such as dual‑agonist peptides and GLP‑1 analogues to achieve weight loss, improve glycaemic control, and lower cardiovascular risk.
- Testing of weight‑loss therapies including dual‑agonist peptides
- Comparison of GLP‑1/GIP receptor agonists on body weight and HbA1c
- Investigation of cardiovascular outcome benefits in diabetic cohorts
- Evaluation of metabolic improvements and safety profiles
- Assessment of treatment impact on obesity‑related comorbidities
The overarching aim is to provide effective, integrated solutions for metabolic disease management and to reduce the burden of associated cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Centre Hungarian Defence Forces
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis | Gilead Sciences Inc. | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 3 | Unknown | 2023-08-04 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.